Abstract:Novel hydrogel microneedles have the advantages of safely loading multiphase drugs, sustained release, and controlled release. It has great potential application in the field of microneedle transdermal drug delivery. In this paper, the optimization process of the cross-linked hyaluronic acid microneedle patch was studied, and the performance of the microneedle patch was evaluated. Under alkaline conditions, hyaluronic acid was cross-linked with 1,4-butanediol diglycidyl ether (BDDE). The cross-linked hyaluronic acid microneedles (cHA-MN) were fabricated by micro-casting method, and the process was optimized. To verify whether the prepared microneedle patch can meet the requirements of use, its appearance, mechanical properties, in vitro insertion properties, and swelling properties were characterized. The results show that the cHA-MN patch prepared by the optimal process has excellent mechanical properties, which allows it to be inserted into the skin smoothly. In addition, the swelling function can also be realized. This provides the possibility for the subsequent use of cHA-MN for continuous drug delivery. The prepared microneedles were loaded with 2.5% dexibuprofen. The results of in vitro transdermal diffusion show that the microneedles release about 38% of the drug in 0~6 h, and then slowly release to 42 h, with a cumulative release rate of about 90%.